PlumX Metrics
Embed PlumX Metrics

Local application of low level laser therapy in mice ameliorates ovarian damage induced by cyclophosphamide

Molecular and Cellular Endocrinology, ISSN: 0303-7207, Vol: 531, Page: 111318
2021
  • 4
    Citations
  • 0
    Usage
  • 15
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent Blog

A Plague on the Earth, from Barcelona to Buenos Aires

"Is Beato aware of the countless tons of single-use plastic waste that his institute (and all the others) produce every year for churning out yet more garbage in the form of fake research papers?" - Aneurus Inconstans

Article Description

The aim of the present study is to assess whether low level laser therapy (LLLT) can protect ovaries from chemotherapy-induced gonadotoxicity using a mice model of premature ovarian failure induced by cyclophosphamide (CTX). LLLT (64 J/cm 2 ) increased the number of antral follicles whilst decreasing the number of atretic follicles compared to CTX alone. LLLT increased the number of primordial follicles compared with those in the CTX group but they did not differ from those in the control group. LLLT treatment increased the number of AMH-positive follicles compared to CTX alone. LLLT application increased ovarian weight, serum progesterone concentration and P450scc protein levels compared to CTX alone. LLLT reduced the apoptosis in antral follicles and the BAX/BCL-2 ratio compared to CTX alone. Vascular morphology, analysed by CD31 and α-SMA immunostaining, was restored in LLLT-treated ovaries compared to CTX alone. In conclusion, application of LLLT prior to CTX might serve as a promising and novel protocol to preserve female fertility in cancer survivors.

Bibliographic Details

Oubiña, Gonzalo; Pascuali, Natalia; Scotti, Leopoldina; Bianchi, Silvia; May, María; Martínez, Jorge Esteban; Marchese Ragona, Clariana; Higuera, Javier; Abramovich, Dalhia; Parborell, Fernanda

Elsevier BV

Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know